The Detection Performance of 18 F-Prostate-Specific Membrane Antigen-1007 PET/CT in Primary Prostate Cancer : A Systemic Review and Meta-analysis
Journal
Clinical nuclear medicine
Journal Volume
47
Journal Issue
9
Pages
755
Date Issued
2022-09-01
Author(s)
Huang, Ya-Ting
Tseng, Neng-Chuan
Chen, Yen-Kung
Lin, Hsiu-Ying
Huang, Ya-Yao
Hwang, Thomas I S
Ou, Yen-Chuan
Abstract
Multiple tools are now available to determine the requirement for a biopsy to diagnose prostate cancer, and PET/CT with radiolabeled prostate-specific membrane antigen (PSMA)-targeting radiotracers has been recommended for detecting primary prostate cancer. Particularly, the radiotracer 18 F-PSMA-1007 was found to be more favorable for primary tumors compared with other PSMA-targeting radiotracers because of its low clearance via the urinary tract and better image resolution. Thus, we performed a systematic review and meta-analysis to more accurately evaluate the detection performance of 18 F-PSMA-1007 PET/CT in primary prostate cancer patients.
Subjects
F-18-PSMA-1007; PET; CT; prostate-specific membrane antigen; prostate cancer; PSMA; BIOPSY; BIODISTRIBUTION; RADIOTRACERS; RISK; F-18; MRI; MEN; PSA
SDGs
Publisher
LIPPINCOTT WILLIAMS & WILKINS
Type
journal article